お知らせ • Sep 28
TransCode Therapeutics, Inc. Receives Non-Compliance Letter from Staff of Nasdaq
On September 23, 2024, TransCode Therapeutics, Inc. received a letter (the Shareholder Approval Deficiency Letter") from Staff of Nasdaq notifying the Company that it was not in compliance with the shareholder approval requirements set in Nasdaq Listing Rule 5635(d), which require prior shareholder approval for transactions, other than public offerings, involving the issuance of 20% or more of the pre-transaction shares outstanding at less than the applicable Minimum Price (as defined in Listing Rule 5635(d)). The Staff's determination under Listing Rule 5635(d) relates to the offering and issuance on July 22, 2024, by the Company of 10,000,000 shares, representing 137% of the pre-transaction total shares outstanding at a price of $0.30 per share (the Offering"), a 62% discount to the Minimum Price of $0.7925. The Offering was previously disclosed in the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on July 24, 2024. According to published guidance on deeply discounted issuances, FAQ 280, Nasdaq has determined that a discount to the Minimum Price (as defined in Listing Rule 5635(d)) in excess of 50%, typically, precludes a determination that such transaction is a Public Offering." As a result, the Staff determined that the discount in excess of 50% precludes the Offering from being deemed a Public Offering, and since the Company did not obtain shareholder approval, the Company failed to comply with the Shareholder Approval Requirement under Listing Rule 5635(d) (the Shareholder Approval Requirement Deficiency"). The Shareholder Approval Deficiency Letter stated that the Company's Shareholder Approval Requirement Deficiency serves as an additional basis for delisting the Company's securities from The Nasdaq Stock Market and that the Panel will consider the Shareholder Approval Requirement Deficiency at the Hearing in their decision regarding the Company's continued listing on The Nasdaq Capital Market. There can be no assurance that the Panel will grant the Company an additional extension period, that the Company will ultimately regain compliance with all applicable requirements for continued listing on The Nasdaq Capital Market or regarding the continued listing of the Company's common stock on the Nasdaq Capital Market and the Company's common stock could be subject to delisting. As previously disclosed, on August 13, 2024, TransCode Therapeutics, Inc., a Delaware corporation, (the Company") announced that they had received a letter (the Minimum Bid Price Deficiency Letter") from the Listing Qualifications Department (the Staff") of The Nasdaq Stock Market LLC (Nasdaq") notifying the Company that, for the 30 consecutive business day period from July 1 through August 12, 2024, the Company's common stock had not maintained a minimum closing bid price of $1.00 per share (the Minimum Bid Price Requirement") required for
continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2). Normally, a company would be afforded a 180-calendar day period to demonstrate compliance with the Minimum Bid Price Requirement.
However, pursuant to Listing Rule 5810(c)(3)(A)(iv), the Company is not eligible for any compliance period specified in Rule 5810(c)(3)(A) because the Company effected two reverse stock splits over the prior two-year
period with a cumulative ratio of more than 250 shares to one. Separate from and in addition to the Minimum Bid Price Deficiency Letter, as previously disclosed, on August 15, 2024, the Company received a letter (the Stockholders' Equity Requirement Deficiency Letter" and together with the Minimum Bid Price Deficiency Letter, the Prior Deficiency Letters") from the Staff of Nasdaq notifying the Company that it was not in compliance with the minimum stockholders' equity requirement for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(b)(1) requires companies listed on The Nasdaq Capital Market to maintain stockholders' equity of at least $2,500,000 (the Stockholders' Equity Requirement"). The Stockholders' Equity Requirement Deficiency Letter stated that the Company's Stockholders' Equity Requirement Deficiency serves as an additional basis for delisting the Company's securities from The Nasdaq Stock Market and that at a hearing in connection with the Minimum Bid Price Requirement, the Nasdaq Hearings Panel (Panel") will consider the Company's Stockholders' Equity Requirement Deficiency as well. As previously disclosed, the Company timely appealed the determination of the Staff to delist the Company's securities from The Nasdaq Capital Market and has been informed by the Staff that the delisting action referenced in the Staff's Deficiency Letters has been stayed, pending a final written decision by the Panel. The Panel will consider the Company's appeal at an oral hearing scheduled for October 1, 2024 (the Hearing").